PainReform CEO to Present at Aegis Virtual Conference on May 4th
02 5월 2023 - 9:30PM
PainReform Ltd. (Nasdaq: PRFX) ("
PainReform" or
the "
Company"), a clinical-stage specialty
pharmaceutical company focused on the reformulation of established
therapeutics, today announced that Ilan Hadar, Chief Executive
Officer of PainReform, will be presenting at Aegis Conference which
is being held virtually on May 2 – 4, 2023.
Mr. Hadar is scheduled to present on Thursday,
May 4th at 12:00 PM ET. The webcast link to the live presentation
is available here.
Management will also be participating in
one-on-one meetings with qualified members of the investment
community during the conference. To request a meeting, please
contact prfx@crescendo-ir.com.
Aegis Capital Corp. will be hosting three full
days of presentations from companies across industries including
technology, healthcare, automotive, and financial services. Aegis
is bringing together more than forty companies to share their
vision with the investing public. Audience members will have the
chance to pose questions to presenters and panelists, interact with
other participants, and access company presentations and video
recordings of each session.
About Aegis Capital
Corporation
Aegis Capital Corporation "Aegis" has been in business for
roughly 40 years catering to the needs of private clients,
institutions and corporations. Aegis was founded in 1984 and offers
its investment representatives a conflict free service platform and
is able to provide a full range of products and services including
investment banking, wealth management, insurance, retirement
planning, structured products, private equity, alternatives, equity
research, fixed income and special purpose vehicles. Aegis is able
to provide quality service through its primary clearing
relationship with RBC Clearing & Custody whose parent company,
Royal Bank of Canada, is one of the world's leading diversified
financial services companies. Member: FINRA / SIPC.
About PainReform
PainReform is a clinical-stage specialty
pharmaceutical company focused on the reformulation of established
therapeutics. PRF-110, the Company's lead product, currently in
Phase III clinical trial, is based on the local anesthetic
ropivacaine, targeting the post-operative pain relief market.
PRF-110 is an oil-based, viscous, clear solution that is deposited
directly into the surgical wound bed prior to closure to provide
localized and extended post-operative analgesia. The Company's
proprietary extended-release drug-delivery system is designed to
provide an extended period of post-surgical pain relief without the
need for repeated dose administration while reducing the potential
need for the use of opiates. For more information, please visit
www.painreform.com.
Notice Regarding Forward-Looking
Statements
This press release contains forward-looking
statements about our expectations, beliefs and intentions.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. These forward-looking statements are based on
assumptions and assessments made in light of management's
experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be
appropriate. Forward-looking statements in this press release are
made as of the date of this press release, and we undertake no duty
to update or revise any such statements, whether as a result of new
information, future events or otherwise. Forward-looking statements
are not guarantees of future performance and are subject to risks
and uncertainties, many of which are outside of our control. Many
factors could cause our actual activities or results to differ
materially from the activities and results anticipated in forward-
looking statements, including, but not limited to, the following:
our history of significant losses, our need to raise additional
capital and our ability to obtain additional capital on acceptable
terms, or at all; our dependence on the success of our initial
product candidate, PRF-110; the outcomes of preclinical studies,
clinical trials and other research regarding PRF-110 and future
product candidates; the impact of the COVID-19 pandemic on our
operations; our limited experience managing clinical trials; our
ability to retain key personnel and recruit additional employees;
our reliance on third parties for the conduct of clinical trials,
product manufacturing and development; the impact of competition
and new technologies; our ability to comply with regulatory
requirements relating to the development and marketing of our
product candidates; commercial success and market acceptance of our
product candidates; our ability to establish sales and marketing
capabilities or enter into agreements with third parties and our
reliance on third party distributors and resellers; our ability to
establish and maintain strategic partnerships and other corporate
collaborations; the implementation of our business model and
strategic plans for our business and product candidates; the scope
of protection we are able to establish and maintain for
intellectual property rights and our ability to operate our
business without infringing the intellectual property rights of
others; the overall global economic environment; our ability to
develop an active trading market for our ordinary shares and
whether the market price of our ordinary shares is volatile; and
statements as to the impact of the political and security situation
in Israel on our business. More detailed information about the
risks and uncertainties affecting us is contained under the heading
"Risk Factors" included in the Company's most recent Annual Report
on Form 20-F and in other filings that we have made and may make
with the Securities and Exchange Commission in the future.
Contact:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com
Ilan Hadar
Chief Executive Officer
PainReform Ltd.
Tel: +972-54-5331725
Email: ihadar@painreform.com
PainReform (NASDAQ:PRFX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
PainReform (NASDAQ:PRFX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024